Liquaemin, also known as heparin, is an anticoagulant medication commonly used in clinical practice. Derived from animal sources, particularly the liver and lungs, it is a glycosaminoglycan, a type of natural polysaccharide. Liquaemin works by inhibiting the clotting process in the blood, preventing the formation of blood clots or thrombi.
This medication primarily functions by enhancing the activity of antithrombin III, an anticoagulant protein in the body that naturally inhibits blood clotting. By binding to antithrombin III, liquaemin accelerates its anticoagulant activity, specifically by blocking the activity of clotting factors IIa (thrombin) and Xa (activated factor X). This inhibition prevents the conversion of fibrinogen to fibrin, an essential step in blood clot formation.
Liquaemin is administered through intravenous or subcutaneous routes and may also be used in some medical devices, such as dialysis equipment or during open-heart surgeries. It is commonly prescribed in cases of deep vein thrombosis, pulmonary embolism, unstable angina, myocardial infarction, and during certain surgical procedures to reduce the risk of clots. Dosages of liquaemin are determined based on several factors, such as the patient's age, weight, medical condition, and the desired effect.
Like any medication, liquaemin is not without risks or side effects. Proper medical supervision is required for its administration since it can cause bleeding complications or hypersensitivity reactions in some individuals. Therefore, it is crucial to consult a healthcare professional for proper diagnosis, monitoring, and guidance when using liquaemin.
